ATE422364T1 - Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält - Google Patents

Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält

Info

Publication number
ATE422364T1
ATE422364T1 AT99957825T AT99957825T ATE422364T1 AT E422364 T1 ATE422364 T1 AT E422364T1 AT 99957825 T AT99957825 T AT 99957825T AT 99957825 T AT99957825 T AT 99957825T AT E422364 T1 ATE422364 T1 AT E422364T1
Authority
AT
Austria
Prior art keywords
influenza virus
virus preparation
composition
protein
multivalent immunogenic
Prior art date
Application number
AT99957825T
Other languages
English (en)
Inventor
George Cates
Suryaprakash Sambhara
David Burt
Michel Klein
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of ATE422364T1 publication Critical patent/ATE422364T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT99957825T 1998-12-17 1999-12-16 Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält ATE422364T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US21377098A 1998-12-17 1998-12-17

Publications (1)

Publication Number Publication Date
ATE422364T1 true ATE422364T1 (de) 2009-02-15

Family

ID=22796441

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99957825T ATE422364T1 (de) 1998-12-17 1999-12-16 Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält

Country Status (10)

Country Link
US (3) US7169395B1 (de)
EP (1) EP1140164B1 (de)
JP (2) JP4021146B2 (de)
AT (1) ATE422364T1 (de)
AU (1) AU769992B2 (de)
CA (1) CA2355270A1 (de)
DE (1) DE69940406D1 (de)
MX (1) MXPA01006214A (de)
NZ (1) NZ512980A (de)
WO (1) WO2000035481A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040022800A1 (en) * 2000-07-31 2004-02-05 Mark Parrington Respiratory syncytial virus vaccine
US20060110406A1 (en) 2003-02-25 2006-05-25 Medimmune Vaccines, Inc. Refrigerator-temperature stable influenza vaccine compositions
EP2481819A1 (de) 2003-02-25 2012-08-01 MedImmune Vaccines, Inc. Querstromfiltration in der Herstellung von stabilisierten Influenza-Impfstoff-Zusammensetzungen
US20160000902A1 (en) * 2003-07-11 2016-01-07 Novavax, Inc. Combination vaccine for respiratory syncytial virus and influenza
EP2769735B1 (de) * 2004-10-06 2017-04-19 MedImmune, LLC Kühlschranktemperaturstabile Grippeimpfstoff-zusammensetzungen
EP2192917B1 (de) * 2007-08-28 2014-01-29 Baxter International Inc. Verfahren zur herstellung von virusimpfstoffen
JP5518041B2 (ja) * 2008-03-18 2014-06-11 ノバルティス アーゲー インフルエンザウイルスワクチン抗原の調製における改良
AU2009304552B2 (en) 2008-10-16 2015-02-19 Dalhousie University Combination adjuvant formulation
PL2370099T3 (pl) 2008-12-09 2016-10-31 Zmodyfikowane białka F RSV i sposoby ich zastosowania
WO2011011390A1 (en) * 2009-07-20 2011-01-27 Novavax, Inc. Purified recombinant influenza virus ha proteins
US20120237536A1 (en) 2009-09-10 2012-09-20 Novartis Combination vaccines against respiratory tract diseases
EP2729169A1 (de) 2011-07-06 2014-05-14 Nanobio Corporation Impfstoff gegen humanes respiratorisches synzytialvirus
CN104093421A (zh) 2011-09-09 2014-10-08 纳诺碧欧公司 纳米乳液呼吸道合胞病毒(rsv)亚单位疫苗
KR20150138184A (ko) * 2013-02-11 2015-12-09 노바백스, 인코포레이티드 호흡기 세포 융합 바이러스 및 인플루엔자를 위한 조합 백신
EP4477231A3 (de) 2013-08-21 2025-03-19 CureVac SE Kombinationsimpfstoff
US10080792B2 (en) 2013-09-23 2018-09-25 Engen Bio, Inc. Influenza vaccine and therapy
CN104436157A (zh) 2013-09-23 2015-03-25 恩金生物有限公司 流感疫苗和治疗
CA2996007A1 (en) * 2015-09-03 2017-03-09 Novavax, Inc. Vaccine compositions having improved stability and immunogenicity
EP3775174A4 (de) * 2018-03-30 2022-07-06 Georgia State University Research Foundation, Inc. Impfstoffe gegen das respiratorische syncytial-virus (rsv)
WO2020229577A1 (en) * 2019-05-15 2020-11-19 Janssen Vaccines & Prevention B.V. Co-administration of seasonal influenza vaccine and an adenovirus based respiratory syncytial virus vaccine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022726A (en) * 1992-02-03 2000-02-08 Palese; Peter Genetically engineered attenuated viruses
US5562909A (en) 1993-07-12 1996-10-08 Massachusetts Institute Of Technology Phosphazene polyelectrolytes as immunoadjuvants
US5762939A (en) * 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US5976552A (en) 1995-04-28 1999-11-02 Protein Sciences Corporation Virus vaccines
US20030072774A1 (en) 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
US6764682B1 (en) * 1994-06-16 2004-07-20 Aventis Pasteur Limited Adjuvant compositions containing more than one adjuvant
US5612037A (en) 1994-07-26 1997-03-18 Connaught Laboratories, Inc. Influenza virus subunit conjugates
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
US5646033A (en) 1994-11-30 1997-07-08 Dyncorp African green monkey kidney cell lines useful for maintaining viruses and for preparation of viral vaccines
US6020182A (en) 1996-07-12 2000-02-01 Connaught Laboratories Limited Subunit respiratory syncytial virus vaccine preparation
US20020136739A1 (en) * 1996-07-12 2002-09-26 Cates George A. Subunit respiratory syncytial virus preparation

Also Published As

Publication number Publication date
US7169395B1 (en) 2007-01-30
WO2000035481A2 (en) 2000-06-22
JP2007031452A (ja) 2007-02-08
CA2355270A1 (en) 2000-06-22
EP1140164B1 (de) 2009-02-11
AU1544200A (en) 2000-07-03
EP1140164A2 (de) 2001-10-10
JP4021146B2 (ja) 2007-12-12
US20080248057A1 (en) 2008-10-09
WO2000035481A3 (en) 2000-10-26
AU769992B2 (en) 2004-02-12
JP2002532435A (ja) 2002-10-02
MXPA01006214A (es) 2004-09-06
NZ512980A (en) 2003-07-25
US20060159700A1 (en) 2006-07-20
DE69940406D1 (de) 2009-03-26

Similar Documents

Publication Publication Date Title
ATE422364T1 (de) Multivalente immunogenische zusammensetzung, die eine rsv untereinheit zusammensetzung und ein influenzavirus präparat enthält
DE60014076D1 (de) Adjuvans-zusammensetzung, enthaltend saponin und ein immunstimulatorisches oligonukleotid
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
RU94002475A (ru) Фармацевтическая композиция и ее применение для лечения вирусных инфекций
BR9712970A (pt) Método para produção de vacina para proteção contra virus sincitial respiratório, mistura de proteìna de fusão purificada, composição imunogênica
CY1112139T1 (el) Μια φαρμακευτικη συνθεση περιλαμβανουσα κρυσταλλικη ριτοναβιρη μορφη ιι και ενα παρασκευασμα εξ αυτης
WO2002087494A3 (en) Novel vaccine
BRPI9701774B8 (pt) cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
IL106968A0 (en) Potentiation of immunogenic response
CA2014033A1 (en) Compositions and treatments for pneumonia in animals
CA2302833A1 (en) Peptides derived from the attachment (g) protein of respiratory syncytial virus
WO2000062802A3 (en) Vaccine comprising rsv antigen and cpg oligonucleotide
ATE77957T1 (de) Peptid-zusammensetzung fuer die herstellung von malaria-impfstoff, sowie fuer die vorbereitung von diagnostischen einzelteilen fuer den nachweis von malaria-aehnlichen krankheiten.
DE602004001969D1 (de) Orale pharmazeutische Zusammensetzung und Verfahren zu ihrer Herstellung
WO2002009749A3 (en) Respiratory syncytial virus vaccine
MY137570A (en) Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis crohn's disease
BR0200377A (pt) Formulações multiparticuladas de sais de lìtio para ministraçào oral apropriadas para ministração uma vez ao dia
AU5597990A (en) Method for preparing vaccine for dental caries and vaccinal compositions for dental caries used as nasal drop
EP1905449A3 (de) Adjuvants zusammensetzung enthaltend saponin und ein immunstimulierendes oligonukliotid
GR3026619T3 (en) Inactivated respiratory syncytial viral vaccines
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
BR0014246A (pt) Utilização de uma proteìna ompa de enterobactéria, ou um de seus fragmentos, associada a um peptìdeo imunogênico derivado do vìrus respiratório sincicial
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties